These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34906689)

  • 1. Multicompartment systems: A putative carrier for combined drug delivery and targeting.
    Gautam L; Shrivastava P; Yadav B; Jain A; Sharma R; Vyas S; Vyas SP
    Drug Discov Today; 2022 Apr; 27(4):1184-1195. PubMed ID: 34906689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of artificial multicompartment vesosome and dendrosome as prospected drug and gene delivery carriers.
    Paleos CM; Tsiourvas D; Sideratou Z; Pantos A
    J Control Release; 2013 Aug; 170(1):141-52. PubMed ID: 23707326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progresses on active targeting liposome drug delivery systems for tumor therapy].
    Zhang M; Lou C; Cao A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2022 Jun; 39(3):633-638. PubMed ID: 35788534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on the use of liposomes for active tumor targeting in cancer therapy.
    Yan W; Leung SS; To KK
    Nanomedicine (Lond); 2020 Feb; 15(3):303-318. PubMed ID: 31802702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted liposomal drug delivery in cancer.
    Medina OP; Zhu Y; Kairemo K
    Curr Pharm Des; 2004; 10(24):2981-9. PubMed ID: 15379663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes for Tumor Targeted Therapy: A Review.
    Wang S; Chen Y; Guo J; Huang Q
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of nanoscale multicompartment liposomes for combinatory drug delivery.
    Al-Jamal WT; Kostarelos K
    Int J Pharm; 2007 Mar; 331(2):182-5. PubMed ID: 17223294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioaptamer conjugated liposomes for tumor vasculature targeting.
    Mann AP; Bhavane RC; Somasunderam A; Liz Montalvo-Ortiz B; Ghaghada KB; Volk D; Nieves-Alicea R; Suh KS; Ferrari M; Annapragada A; Gorenstein DG; Tanaka T
    Oncotarget; 2011 Apr; 2(4):298-304. PubMed ID: 21666286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug delivery systems using nano-sized drug carriers].
    Nakayama M; Okano T
    Gan To Kagaku Ryoho; 2005 Jul; 32(7):935-40. PubMed ID: 16044950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interdigitation of lipids for vesosomal formulation of ergotamine tartrate with caffeine: a futuristic trend of intranasal route.
    Dali P; Shende P
    Drug Dev Ind Pharm; 2024 Feb; 50(2):124-134. PubMed ID: 38158799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Scope and Challenges of Vesicular Carrier-Mediated Delivery of Docetaxel for the Management of Cancer.
    Misra C; Raza K; Goyal AK
    Curr Drug Deliv; 2020; 17(10):874-884. PubMed ID: 32576129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colloidal systems for tumor targeting.
    Storm G; Crommelin DJ
    Hybridoma; 1997 Feb; 16(1):119-25. PubMed ID: 9085138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting drug release from liposomes.
    Lindner LH; Hossann M
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):111-23. PubMed ID: 20047152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A review on the influences of size and surface charge of liposome on its targeted drug delivery in vivo].
    Yang YF; Xie XY; Yang Y; Zhang H; Mei XG
    Yao Xue Xue Bao; 2013 Nov; 48(11):1644-50. PubMed ID: 24475700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of novel fusogenic vesosomes for transcutaneous immunization.
    Mishra V; Mahor S; Rawat A; Dubey P; Gupta PN; Singh P; Vyas SP
    Vaccine; 2006 Jul; 24(27-28):5559-70. PubMed ID: 16730102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microfluidic Assembly of Monodisperse Vesosomes as Artificial Cell Models.
    Deng NN; Yelleswarapu M; Zheng L; Huck WT
    J Am Chem Soc; 2017 Jan; 139(2):587-590. PubMed ID: 27978623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of liposomes as dental drug delivery systems.
    Nguyen S; Hiorth M; Rykke M; Smistad G
    Eur J Pharm Biopharm; 2011 Jan; 77(1):75-83. PubMed ID: 20875853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer.
    Kumar Giri T; Giri A; Kumar Barman T; Maity S
    Anticancer Agents Med Chem; 2016; 16(7):816-31. PubMed ID: 26567624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal drug delivery systems: an update review.
    Samad A; Sultana Y; Aqil M
    Curr Drug Deliv; 2007 Oct; 4(4):297-305. PubMed ID: 17979650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
    J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.